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Our previous studies demonstrated arsenic trioxide- (ATO-) induced selective tumor vascular disruption and augmentation
of thermal or radiotherapy eﬀect against solid tumors. These results suggested that a trimodality approach of radiation, ATO,
and local hyperthermia may have potent therapeutic eﬃcacy against solid tumors. Here, we report the antitumor eﬀect of
hypofractionated radiation followed by ATO administration and local 42.5◦C hyperthermia and the eﬀects of cisplatin and
thermoradiotherapy. We found that the therapeutic eﬃcacy of ATO-based thermoradiotherapy was equal or greater than that
of cisplatin-based thermoradiotherapy, and marked evidence of in vivo apoptosis and tumor necrosis were observed in ATO-
treated tumors. We conclude that ATO-based thermoradiotherapy is a powerful means to control tumor growth by using vascular
disruption to augment the eﬀects of thermal and radiation therapy.
1.Introduction
As2O3 (ATO) has now been widely studied and used
successfully as a therapeutic agent for acute promyelocytic
leukemia, as it causes diﬀerentiation and apoptosis of
leukemic cells [1–6]. This FDA-approved compound has also
demonstrated signiﬁcant potential as a solid tumor anti-
vascular and angiogenesis inhibiting agent in preclinical
studies. We were among the ﬁrst groups to discover the
potentandselectivetumorvasculardisruptioncausedbythis
agent [7]. Subsequently we have demonstrated signiﬁcant
thermosensitization of tumors and an increase in tumor
response to radiation therapy induced by ATO treatment
[8–10]. Although there have been numerous reports in the
literature, relatively little is clear about the cellular and
physiological mechanisms of ATO eﬀect on solid tumors
in vivo,e s p e c i a l l yi nr e g a r dt oa n t i v a s c u l a re ﬀects of the
drug and how to use these eﬀects to design eﬀective clinical
regimens [7, 11–14].
From our earlier ﬁndings, we concluded that selective
tumor vascular shutdown caused by ATO induced boldly
demarcated necrotic regions. We also observed an increase
in mean or median tumor oxygenation values for up
to a week after ATO therapy [9, 10, 15]. These studies,
and the low toxicity caused by ATO in our experience,
suggested that a regimen consisting of radiation, ATO, and
local hyperthermia may be more eﬀective than the already
clinically used cisplatin-based combination therapy.
Phase III clinical studies using thermoradiotherapy with
cisplatin have begun [16]. This clinical trial was expanded
to a multicenter, international trial against cervical can-
cer due to the encouraging initial results. More than 15
diﬀerent Phase I, II, or III studies to compare the eﬀects
of cisplatin/radiation and heat/cisplatin/radiation have been
performed in the past 20 years [17]. However, use of ATO,
a vascular disrupting agent with a diﬀerent mechanism of
action than conventional cisplatin therapy and which may be
eﬀectiveinpatientsresistantorinsensitivetoplatinum-based2 Journal of Oncology
regimens, could be a better candidate for the treatment
of solid tumors. The possible advantages of a tumor and
stromal- (i.e., vascular-) targeted multimodality approach to
improved cancer treatment are discussed in the context of
using ATO or similar vascular disrupting agents to sensitize
the tumor to thermoradiotherapy.
2.MaterialsandMethods
2.1. Cell Line
FSaII Tumor. This ﬁbrosarcoma of C3H mice (Jackson Lab-
oratories) was originally obtained from Dr. Herman Suit
(Massachusetts General Hospital). Stock cells are stored in
liquid nitrogen, and new cultures are established every 2-3
months. FSaII tumor cells grow well in RPMI-1640 medium
supplemented with 10% bovine calf serum.
2.2. Tumor Induction. FSaII tumor cells in exponential
growth phase were harvested using 0.25% trypsin in Hepes-
buﬀered medium, washed, and counted. A subcutaneous
injection of 2 × 105 cells in 0.05mL serum-free medium was
made in the hind thigh of female C3H mice.
2.3. Arsenic Trioxide. An i.p. injection of 4–8mg/kg arsenic
trioxide (ATO or TrisenoxTM, Cephalon Oncology, Inc.,
Frazer, Pa, USA) was performed by using a clinical grade
1mg/mL stock solution for each mouse, and imaging
or treatment was performed at speciﬁc times after this
injection. Control mice were injected with an equal volume
of phosphate-buﬀered saline, pH 7.4.
2.4. Cisplatin. Doses of 2 or 6mg/kg cisplatin (Sigma-
Aldrich, St. Louis, Mo, USA) were administered i.p. in saline
at the frequency indicated for each of the studies comparing
to ATO treatment.
2.5. Window Chamber Tumor Growth and Intravital Micro-
scopy. Skin-fold chambers made of anodized aluminum
frames were surgically implanted into a fold of dorsal skin in
female nu/nu mice. Brieﬂy, the dorsal skin was sandwiched
between two identical anodized round aluminum frames.
The 19mm × 22mm chamber was held ﬁxed on the
mouse by three screws between the frames. The skin was
also attached to the chamber with 4-O silk. The skin on
both sides of the viewing region was removed, exposing
the dermis containing the microvasculature. Excess fascia
on the dermis was removed to assist clear visualization of
the microvasculature. Windows milled from quartz glass
microslides (Chase Scientiﬁc Glass, Rockwood, Tenn, USA)
were used to cover the vascular area. The distance between
the windows was maintained at 450µm by a spacing gasket
ontheinsideoftheframes,leavingroomforseededtumorto
grow. 1-2 × 106 tumor cells were added in 30uL of matrigel
just before placement of the glass windows. Treatments and
imaging were performed over the course of tumor growth
and treatment as described [18].
2.6. FLIVO Reagent. FLIVO (FAM-VAD-FMK, 50µgp e r
vial, Immunochemistry Technologies, LLC, Bloomington,
Minn, USA) was dissolved in 50µL of DMSO and diluted by
the addition of 200µL of sterile PBS, pH 7.4. At 30min after
an i.v. injection of 0.1mL of FLIVO cell permeant probe via
the lateral tail vein, ﬂuorescent images were captured at 20X
using a Hamamatsu C2400 camera (Hamamatsu, Japan) and
Broadway Imaging Software (Data Translation, Marlboro,
Mass, USA) on an Eclipse TE200 bench-top microscope
(Nikon, Japan).
2.7. Histological Analysis. Tumor-bearing mice were sacri-
ﬁced, and the tumor was removed at the speciﬁed time
point after treatment. The tissue was ﬁxed in 10% neutral
buﬀered formalin, and, after processing and embedding,
tissue sections at 5µM were prepared and stained with
hematoxylin and eosin. An Olympus BX40 microscope was
used to image multiple ﬁelds at 20x magniﬁcation which
were then ﬁt together using Adobe Photoshop.
2.8. X-Irradiation. Tumors were locally irradiated with 5Gy
per fraction by a Philips 250Kv X-ray machine at a dose rate
of 1.4Gy/min. The body was shielded with lead with only the
tumor and foot exposed to the X-ray beam.
2.9. Hyperthermia. Tumors were heated by immersing the
tumor-bearing legs of anesthetized mice into preheated
water for 60min as described previously [8]. The water
temperature and the temperature of tissues were routinely
measured with needle-type (29 gauge) thermocouples. The
thermoproﬁles in tumors and normal tissues during water-
bath heating have been thoroughly studied in our group [8].
The temperature in the tumors during water bath heating
is consistently 0.3–0.5◦C below the water temperature. All
temperatures quoted refer to the water temperature during
hyperthermia treatment.
2.10. Assessment of Tumor Growth. Tumor volume was mea-
sured with a caliper (Scienceware) and calculated according
to the equation: (a2 × b)/2, where “a” is the width and “b”
the length of the tumor.
3. Results
As shown in Figure 1(a) cisplatin at 2mg/kg i.p. and
Figure 1(b) ATO at 8mg/kg i.p. given every 4 days for a total
of three treatments were able to signiﬁcantly improve the
antitumor eﬀect of radiation combined with hyperthermia
against FSaII tumors. The single modalities were only
slightly eﬀective, and the dual-modality combinations fur-
ther improved the tumor growth delay, but the trimodality
treatments were clearly the most eﬀective in delaying tumor
growth, especially in the case of ATO where an approximate
2-fold increase in growth delay compared to any other
treatment occurred (P<0.001 by day 8 of therapy onward).
Cisplatin-based thermoradiotherapy was only signiﬁcantly
diﬀerent from the dual-modality treatments by day 16 after
start of treatment (P = 0.03).Journal of Oncology 3
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Figure 1: Comparison of arsenic trioxide and cisplatin enhanced thermoradiotherapy of FSaII ﬁbrosarcoma tumors applied every 4 days as
indicated by the arrows on the x-axis. Cisplatin was given at 2mg/kg, while ATO was given at 8mg/kg. Radiation fractions were 5 Gy, and
hyperthermia was applied at 42.5◦C (60min). In the dual- or trimodality treatment groups, radiation was given ﬁrst, followed by ATO or
cisplatin injection within 30min and hyperthermia was applied beginning 2h after the completion of radiation. N = 5–7 mice per group.
Errors bars represent 1 SEM.
In order to more deﬁnitively understand the potential
of ATO as a part of a trimodality regimen, we did a
subsequent study using an equimolar amount of cisplatin or
ATO (4mg/kg ATO MW: 198 versus 6mg/kg cisplatin MW:
300, resp.). In this study, ATO was again found to be more
eﬀective than cisplatin in augmenting the eﬀects of radiation
and hyperthermia on tumor inhibition (P = 0.02 versus
cisplatin-based therapy by day 10 after start of treatment). As
shown in Figure 2, ATO maximally increased tumor growth
delay by a factor of 2.5-fold as compared to control tumor
growth, while cisplatin increased the tumor growth delay
response by a factor of about 2-fold on average compared to
control tumors in this group of animals.
A typical composite image of the entire tumor gross
section from an untreated tumor and from tumors treated
with either cisplatin-based or ATO-based trimodality ther-
apy is shown in Figure 2 (inset). The eﬀects of repeated
radiation, arsenic trioxide, and heat treatments are clearly
evident in the marked rings of live and dead regions of tissue
in the ATO-treated mouse, while the cisplatin-based therapy
indicates there were more widespread regions of viable
tumor remaining after treatment and the control tumor
shows homogenous staining of live cells with very little
architectural variation. The images shown are the typical
results obtained from groups of 3 control or trimodality-
treated tumors that were prepared for histology and studied.
We subsequently investigated the in vivo cellular and
physiological mechanisms by which ATO selectively damages
solid tumor and increases the eﬀect of hyperthermia and
radiation. We employed the dorsal skin-fold window cham-
ber (DSFC) technique for intravital imaging of tumor tissue
[18–21] to visualize real-time changes in tumor physiology
andvascularity.AsshowninFigure 3,ATOcausessubstantial
and noticeable vascular damage in relatively large areas of
the tumor by 2h after i.p. injection of tumor bearing mice.
A ﬂuorescent pan-caspase probe (FLICA or FLIVO Poly-
(pan) caspase detection) was used for in vivo assessment
of cell death and viability, as we previously reported [21].
Figure 4showschangesintheamountofapoptosisoccurring
in FSaII tumors grown in the window chamber in control
tumors, 2h after a single dose of 8mg/kg ATO i.p., 2h
after 5Gy followed by 30min of 42.5◦C heating or 2h after
5Gy and 8mg/kg ATO i.p. followed by 42.5◦C heating, as
detected by the polycaspase inhibitor. There appeared to be
increased apoptotic activity in the representative regions of
the tumor in the mouse treated with ATO alone as well as
the mouse that received trimodality treatment compared to
control tumor or tumor treated with heat and radiation. An
intensity plot was made for each image (Figure 4), and the
overall mean pixel intensity was calculated for each group.
Upon statistical analysis of the mean intensity values, the
trimodalitymeanpixelintensitywasfoundtobesigniﬁcantly
increasedcomparedtocontrol,ATOalone,orheatcombined
with radiation exposure (P<0.03). ATO treatment alone
appearedtovisuallycausemoreapoptosisthanthatintumor4 Journal of Oncology
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Figure 2: Equimolar comparison of arsenic trioxide and cisplatin as part of a recurring trimodality regimen every 4 days against FSaII
ﬁbrosarcoma tumors. As in the previous ﬁgure, in the dual- or trimodality treatment groups, radiation was given ﬁrst, followed by ATO or
cisplatin injection within 30min and hyperthermia was applied beginning 2h after the completion of radiation. N = 6–8 mice per group.
Error bars represent 1 SEM. INSET: histological evidence of antitumor eﬀects of repeated trimodality therapy applied every 4 days, 3 times
in total in FSaII tumors (tumors taken from treatment groups on the last day of measurement) compared to control tumor.
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Figure 3: Representative window chamber imaging of 8mg/kg i.p. arsenic trioxide-induced vascular damage in FSaII ﬁbrosarcoma grown
in nude mice. FSaII tumor was implanted and 7 days later the tumor was imaged before and 2h after an i.p. injection of 8mg/kg ATO. The
tumor is outlined in black and the boxes have been placed in the areas where typical marked evidence of vascular damage occurred.
treated with heat combined with radiation or in control
tumor, but this was not found to be statistically signiﬁcant.
4. Discussion
The results of the current study suggest that fractionated
radiation in concert with arsenic trioxide and clinically
achievable thermal doses is a viable option against tumors
thatmaynotbeadequatelytreatedbymono-ordual-therapy
regimens or may be insensitive to conventional cisplatin-
based chemotherapy. Our results agree with a number of
other intriguing studies employing a variety of trimodality
approaches, some with other antivascular or antiangiogenic
agents [22–30]. In view of these results and the clinical
beneﬁtobtainedwithtrimodalityapproachesinvolvingmore
traditional therapeutics [16, 17, 26, 31, 32], continued
development and implementation of this treatment strategy
appears to be promising.
Many previously studied triple-combination regimens
do not include hyperthermia, but instead pair an antiangio-
genic or other biological targeting agent with more standard
chemotherapy and radiation [25, 33] .T h e s et y p eo fs t u d i e s
are intriguing, but it should be noted that they are quite
diﬀerent from studies employing thermal therapy since theJournal of Oncology 5
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Figure 4: ATO, heat, and radiation induce apoptotic activity by 2h after combined treatments in tumor of treated mouse. In vivo imaging of
polycaspase inhibitor in FSaII tumor grown in the window chamber and treated with 8mg/kg arsenic trioxide, thermoradiotherapy (dual-
modality, 5Gy followed by 42.5◦C (30min) 2h later), or arsenic trioxide combined with thermoradiotherapy (trimodality; 5Gy, 8mg/kg
ATO, 2h, 42.5◦C (30min). The right insets are intensity plots of the images on the left, created in Matlab. µ: mean pixel intensity for all pixels
in each image. The color bar represents the relative intensities of individual pixels.
mechanism of action and rationale for sequencing will likely
be very diﬀerent for each strategy. Work with the vascular-
targeting agent combretastatin has been highly encouraging
and supports the intelligent use of agents that target the
tumor vasculature in heat-based multimodality regimens
[29, 30, 34, 35]. However, the authors of these preclinical
and clinical studies all highlight the critical need for well-
controlled clinical trials where the sequencing of the agents
is of utmost importance. These studies and our rationally
designedstudybasedonknownsynergismofATO,radiation,
and hyperthermia strongly suggest that careful attention to
how treatments are combined will maximize the beneﬁts for
patients.
Our earlier work had demonstrated enhancement of
radiation-induced growth delay when ATO was given before
or after radiation. However, since we knew that tumor
blood ﬂow was rapidly reduced or abolished in certain
regions of the tumor upon ATO administration, it appeared
logical to avoid induction of hypoxia before radiation
by administering ATO after each radiation fraction. The
application of heat to the tumor was elected to be after
the radiation and the ATO injection for two reasons. First,
although there may be a beneﬁt in increasing the tumor
oxygenation and thus the tumor radiosensitivity when heat
is applied prior to radiation, we had observed a more
signiﬁcant thermosensitization when heat was applied after
ATO injection at the point of greatest blood ﬂow shutdown.
Secondly, it is well known that radiation damage repair
is inhibited by heating after radiation exposure. Therefore,
the combination of ATO-induced tumor and endothelial
thermosensitivity and potential inhibition of DNA damage
repair were expected to cause the greatest improvement in6 Journal of Oncology
radiation-induced tumor growth delay. Indeed, the tumor
growth was suspended in some animals during the period of
therapy, suggesting that continued therapy may even obtain
tumor cures using this multimodality approach. It is possible
that other sequences and/or frequencies of treatment may be
even more potent in these models. The important result is
that arsenic trioxide, as a novel vascular disrupting agent,
can be eﬀectively added to a thermoradiotherapy regimen
that may have certain advantages and synergy compared to
regimens employing traditional chemotherapy.
We further studied the eﬀects of ATO alone or in
combination with heat and radiation therapy on tumor
blood ﬂow and apoptosis in vivo by employing intravital
microscopy and histological analysis. A current focus of our
group is to delineate the kinetics of vascular cell apoptosis
and tumor cell apoptosis after these treatments. Ultimately,
apoptosis detection in vivo could be used as a surrogate
marker of treatment response in clinical situations. Overall,
we have clearly demonstrated here, and previously, that ATO
can be a powerful radiation- or thermosensitizing agent [8,
9]. Others have also recently found signiﬁcant eﬀects of ATO
therapy on the tumor control obtained by thermal ablation
or fractionated radiation therapy [11, 36]. Newer agents
basedontrivalentarsenicalsthatmayselectivelytargettumor
endothelium have reached clinical trials, and; thus, there is
reason to believe that acceptable clinical doses of arsenic-
based therapy would be achievable in the clinic and/or better
delivery strategies will be available and contribute to positive
therapeutic outcomes [13, 37, 38].
Equal or better antitumor activity of arsenic trioxide-
based thermoradiotherapy was observed in our study com-
pared with a cisplatin-based regimen. The study with cis-
platin at equimolar ratio to ATO (Figure 2) was particularly
enlightening in that it allows us to hypothesize that ATO
has the potential to improve upon currently employed
trimodalitytherapyagainstcervicalcancer.Outoftheseveral
antivascular strategies currently being tested either preclini-
cally or in clinical trials, it seems likely that at least one of
these agents will become a realistic option to the clinician
wanting to maximize the eﬀects of a thermoradiotherapy
treatment plan.
5. Conclusions
Clinical trial development of an arsenical-based trimodality
strategy may be warranted, especially in view of the wealth
of clinical experience already accumulated with arsenic
against leukemia, lymphoma, and other solid tumors. The
continued success of several radiation-, chemotherapy- and
hyperthermia-based trials suggest that there is much to be
gained with agents that selectively target and disrupt solid
tumor vasculature and angiogenic capability with diﬀerent,
yet complementary, mechanisms of action such as ATO,
thermal therapy, and radiation therapy.
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